At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 53 enrolled
Drug / intervention
Netupitant +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Netupitant, Palonosetron, and 3 other interventions for Malignant Neoplasm and 2 related conditions. Completed, enrolled 53 participants across 1 site.
Detailed Summary
This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Neoplasm, Nausea, Vomiting
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Helsinn Healthcare SA
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMay 2017
Primary CompletionFeb 2022
TodayJul 2026
First PostedFeb 2, 2017
Enrollment StartMay 3, 2017
Primary CompletionFeb 14, 2022
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 9.4 years ago
Interventions
Netupitantdrug
Given PO
Palonosetrondrug
Given PO
Palonosetron Hydrochloridedrug
Given PO
Placeboother
Given PO
Questionnaire Administrationother
Ancillary studies